In an interview at the TIDES USA conference in San Diego, Calif., Sung Jun Park, Project Manager, Global Business, at Hanmi Fine Chemical, discusses the company’s role as a leading CDMO company in South Korea and its expertise in manufacturing active pharmaceutical ingredients. Park highlights Hanmi’s recent expansion into mRNA raw materials and the company’s primary product, Hanmi Cap, a novel cap analog structure used in the in vitro transcription of mRNA. Additionally, Park shares recent developments in cap candidates for self-amplifying RNAs.